- Shilpa Medicare Limited has entered into a binding agreement with Switzerland-based NXI Therapeutics AG to develop and manufacture a New Chemical Entity targeting autoimmune and alloimmune disorders.
- The partnership supports Shilpa’s strategy to expand its CDMO capabilities and strengthen its position in high-value biologics and specialty therapeutics.
Shilpa Medicare Limited (SML) has entered into a binding agreement with NXI Therapeutics AG, a Swiss-based company, to develop and manufacture a New Chemical Entity (NCE) targeting autoimmune and alloimmune disorders. The collaboration marks a step in Shilpa’s expansion within the high-value biopharmaceutical sector.
The agreement focuses on the development of an NCE designed to address complex autoimmune and alloimmune conditions, areas identified as having significant unmet medical needs. Through this partnership, Shilpa will leverage its integrated development and commercial manufacturing infrastructure to support the program from development through scalable production.
The collaboration aligns with Shilpa’s stated strategy of evolving as an innovation partner for global biotech companies. By engaging in early-stage, innovation-driven pipelines, the company aims to strengthen its Contract Development and Manufacturing Organization (CDMO) platform and expand its presence in differentiated and high-growth therapeutic markets.
Management commentary accompanying the announcement highlighted momentum in high-value biologics and specialty therapeutics. The company indicated that the partnership is expected to enhance long-term growth visibility for its CDMO business and deepen its expertise in innovative therapies.
For NXI Therapeutics AG, the agreement provides access to Shilpa’s development and manufacturing capabilities to advance the NCE toward commercial potential.
